Brand-name GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved, manufactured under strict quality standards, and go through the full regulatory approval process; compounded versions are custom-prepared by compounding pharmacies and, as of 2026, operate under significantly narrower legal circumstances than they did during the height of the 2022 to 2024 supply shortages, since both semaglutide and tirzepatide are no longer officially in shortage.
Why compounding was so widespread during the shortage years?
When brand-name semaglutide and tirzepatide were in short supply, FDA rules allowed compounding pharmacies to prepare versions of these medications to help meet patient demand that manufacturers couldn't fill. This created a lower-cost alternative that became widely used, particularly through telehealth platforms, during a period when brand-name products were genuinely difficult to obtain.
Why the legal landscape has changed?
The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, which removed the primary legal basis that allowed large-scale compounding of these medications. Since then, regulatory oversight has continued tightening: the FDA has taken further steps to restrict the pathways compounding pharmacies and outsourcing facilities can use to produce these medications, meaning compounded semaglutide and tirzepatide are far less broadly available through legitimate channels than they were during the shortage period, with the regulatory picture continuing to evolve.
What this means for safety and quality?
Brand-name medications undergo FDA review of manufacturing consistency, purity, and dosing accuracy as part of the approval process. Compounded medications, particularly from less rigorous sources, don't go through that same standardized review, which means there's more variability in quality and dosing accuracy between different compounding sources — a real consideration for a medication where precise, consistent dosing matters for both safety and effectiveness.
What to consider given the current landscape?
Given both the tightening regulatory environment and the inherent quality variability of compounded products, brand-name medications, obtained through a legitimate prescription, are generally the more straightforward and reliable path today for most patients. If cost is the primary barrier, it's worth discussing insurance coverage, manufacturer savings programs, and dosing strategies with your provider, rather than defaulting to a compounded product purely based on price, given how much the legal and safety picture has shifted since the shortage years.
What questions are worth asking?
If you're considering any GLP-1 medication, whether brand-name or compounded, it's reasonable to ask your provider directly about the source of the medication, the pharmacy's licensing and reputation, and current regulatory status — this is a fast-moving area, and what was true a year or two ago may no longer reflect where things stand today.
How do you make an informed decision?
Our clinical team stays current on the regulatory landscape around GLP-1 medications and can walk you through your options, current pricing realities, and what's appropriate given where things stand today.